Q32 Bio Inc.QTTBNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank11
3Y CAGR-18.8%
5Y CAGR-28.2%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
-18.8%/yr
vs -7.0%/yr prior
5Y CAGR
-28.2%/yr
Recent acceleration
Acceleration
-11.8pp
Decelerating
Percentile
P11
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
2025$19.16M-60.2%
2024$48.14M+51.7%
2023$31.73M-11.4%
2022$35.81M-61.5%
2021$93.08M-7.3%
2020$100.39M+12.3%
2019$89.40M+86.4%
2018$47.95M+124.3%
2017$21.38M+275.4%
2016$5.69M-